Lengo Therapeutics Announces Expansion of its Executive Leadership Team with Appointments in R&D, CMC and FinanceBusiness Wire • 09/14/21
All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Strong BuyZacks Investment Research • 10/15/19
Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SECGlobeNewsWire • 10/11/19
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of MigraineGlobeNewsWire • 10/10/19
This Biotech Stock Just Rocketed 83% On A $2 Billion Takeover DealInvestors Business Daily • 09/16/19
Danish Company To Buy Migraine Drug Developer Alder Biopharma In Deal Worth Up To $1.95BBenzinga • 09/16/19
Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout dealMarket Watch • 09/16/19
Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cashGlobeNewsWire • 09/16/19
Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache SocietyGlobeNewsWire • 09/05/19
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 08/30/19
Alder BioPharmaceuticals, Inc. (ALDR) CEO Bob Azelby on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to BuyZacks Investment Research • 07/03/19
Alder Biopharmaceuticals, Inc. (ALDR) CEO Bob Azelby on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/03/19
Why This Migraine-Focused Biotech Stock Could Be The Next TakeoverInvestors Business Daily • 04/23/19